Intranasal Peptides Compared: Semax, Selank, PT-141 and Kisspeptin Research

For most peptides, intranasal bioavailability is less than 5% in humans — but for specific compounds with small molecular weights and CNS targets (Semax, Selank, PT-141, Kisspeptin), the nasal route achieves bioavailability that rivals or exceeds injection while providing direct nose-to-brain access that bypasses the blood-brain barrier entirely.

This guide covers the 4 research peptides most commonly administered intranasally — with published bioavailability data, the molecular-weight and CNS-target rationale for why intranasal works for these compounds specifically, the route-selection framework ("use the route that was actually studied"), administration technique, and the specific reason the FDA halted intranasal PT-141 clinical development in 2007. It stays focused on injectable research peptides that happen to have an intranasal research history — not cosmetic nasal sprays, not recreational protocols, not products sold by nasal spray retailers.

For injection-based administration (the standard route for most research peptides), see the injection guide. For route selection between subcutaneous and intramuscular injection, see the SubQ vs IM comparison.

Why Intranasal Delivery Works for Specific Peptides (and Fails for Most)

The nasal mucosa is a thin epithelium (~200 μm) with rich capillary vascularization and direct neural connections to the central nervous system via the olfactory and trigeminal nerves. When a peptide is deposited on this surface, three things happen simultaneously: a small fraction crosses into systemic circulation through mucosal capillaries, a smaller fraction is transported directly into the brain via the nose-to-brain pathway (olfactory bulb → cortex, hypothalamus, and other CNS regions), and the majority is degraded by proteolytic enzymes in the olfactory epithelium or cleared by mucociliary action.

For the vast majority of peptides, the enzyme barrier and molecular weight constraints mean bioavailability ends up below 5% — which is why injection dominates the peptide market. But two specific factors flip this calculation for certain compounds:

Molecular weight. Effective intranasal delivery works for peptides up to approximately 6,000 Da, with a practical upper limit around 25–30 kDa. Above this threshold, transmucosal absorption becomes unreliable because the nasal cavity simply isn't designed to absorb large molecules. Semax (813 Da) and Selank (751 Da) are both small heptapeptides that sit near the low end of the peptide size range — their molecular profile is essentially optimal for nasal absorption.

CNS target. The direct nose-to-brain pathway is meaningful only for peptides whose biological target is inside the brain. Semax acts on BDNF and neurotrophic signaling in the CNS. Selank modulates GABA receptor expression and neurotransmission. PT-141 activates MC4R receptors in the hypothalamus. Kisspeptin stimulates GnRH release from hypothalamic neurons. For these compounds, direct CNS delivery is a meaningful advantage over injection — the peptide reaches its target without crossing the blood-brain barrier.

This is why GLP-1 agonists, BPC-157, TB-500, and GH secretagogues do not use the intranasal route. Their targets are peripheral — GI tract, injured tissues, or the anterior pituitary — which subcutaneous injection reaches directly through systemic circulation. Adding a nose-to-brain component would not improve the therapeutic outcome for these compounds, and their molecular weights (semaglutide ~4,100 Da, TB-500 ~5,000 Da) are at or above the practical absorption limit.

The 4 Peptides Most Commonly Administered Intranasally

The peptides most commonly administered intranasally share two features: molecular weight under ~1,500 Da and central nervous system targets — this includes Selank, Semax, PT-141, and Kisspeptin, each with distinct bioavailability profiles and clinical research histories.

Selank — The Highest-Bioavailability Intranasal Peptide

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro, 751 Da) derived from tuftsin, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Its Pro-Gly-Pro C-terminal extension stabilizes it against rapid proteolysis, which is a key reason its bioavailability is unusually high for a peptide.

Pharmacokinetic studies using radiolabeled Selank in rats (Zolotarev et al., 2005–2006) documented intranasal systemic bioavailability of approximately 92.8% with detectable blood levels within 30 seconds of administration. Rat brain uptake reached approximately 1.04% of the administered dose — low in absolute terms but meaningful given the direct nose-to-brain pathway. Selank is approved in Russia as a nasal spray for generalized anxiety disorder and neurasthenia, with efficacy described in clinical studies as comparable to benzodiazepines but without sedation, tolerance, or dependence.

The clinical significance: Selank's research literature is built entirely on the intranasal route. Switching to subcutaneous injection (as some community protocols do) changes the absorption profile and moves the user outside the evidence base.

Semax — The Neuroprotective Heptapeptide

Semax is a synthetic analog of ACTH(4-10), a heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro, 813 Da) developed by the Institute of Molecular Genetics of the Russian Academy of Sciences in the late 1980s. It is approved in Russia as a nasal spray for stroke recovery, traumatic brain injury, and cognitive optimization.

Rat pharmacokinetic studies documented maximum plasma concentrations of approximately 1.69% of the administered intranasal dose, with maximum brain uptake reaching 0.13%. The brain-to-plasma ratio confirms CNS delivery via the nose-to-brain pathway rather than simple peripheral absorption followed by blood-brain barrier crossing. Semax undergoes relatively rapid enzymatic degradation in nasal mucus (Met-Glu cleavage is a primary degradation pathway), which is why N-acetyl-Semax modifications have been developed to improve stability.

Like Selank, Semax's clinical and pharmacokinetic literature is based on intranasal administration. Injectable Semax exists in community protocols, but the bioavailability and effect timelines described in the published research reflect nasal delivery.

PT-141 (Bremelanotide) — The Melanocortin MC4R Agonist

PT-141, also known as bremelanotide, is a cyclic heptapeptide (1,025 Da) derived from alpha-MSH. It activates MC4R receptors in the hypothalamus, producing effects on sexual arousal and desire. PT-141 has a uniquely conflicted development history regarding intranasal administration.

Phase II clinical trials in the mid-2000s tested intranasal bremelanotide in men with erectile dysfunction at doses of 5–15 mg as on-demand nasal sprays administered approximately 45 minutes before sexual activity. One large placebo-controlled trial presented at the 2007 AUA meeting enrolled 726 men with ED (average age 55) over 12 weeks. Doses of 7.5 mg and above produced statistically significant improvements in IIEF scores compared to placebo. Efficacy was dose-dependent, with higher intranasal doses yielding better erectile responses.

However, the FDA halted intranasal bremelanotide clinical development in 2007 due to variable blood pressure responses — particularly transient hypertension — that were deemed too unpredictable for approval. Development pivoted to subcutaneous administration, which showed more consistent absorption and a more predictable BP profile. Subcutaneous bremelanotide (Vyleesi) received FDA approval in 2019 for hypoactive sexual desire disorder in premenopausal women.

Intranasal PT-141 compounded formulations still exist — typically at concentrations around 1.25 mg per spray — and are still used in research contexts, but they do not have FDA backing and carry the same blood pressure variability that stopped the original clinical program.

Kisspeptin — Emerging Intranasal Research

Kisspeptin is a decapeptide (~1,300 Da) that stimulates GnRH release from hypothalamic neurons, making it an upstream regulator of the reproductive hormone axis. Human research on kisspeptin has been led primarily by Imperial College London, with randomized controlled trials published in JAMA Network Open examining kisspeptin's effects on reproductive function and sexual arousal.

Most published human kisspeptin research uses intravenous or subcutaneous administration. Intranasal kisspeptin is emerging in research but less established than for Semax, Selank, or PT-141. For users considering kisspeptin protocols, the injectable route has stronger clinical literature support at this point.

Oxytocin — The Pharmaceutical Context

Oxytocin (1,007 Da nonapeptide) is commonly administered intranasally in social bonding, attachment, and emotional regulation research — typically at doses around 24 IU. However, oxytocin is a pharmaceutical peptide (FDA-approved as Pitocin/Syntocinon for labor induction), not a research peptide in the same category as the others covered here. Peptigrity does not maintain a compound page for oxytocin because it falls outside the research peptide scope. Users interested in oxytocin protocols should work with a compounding pharmacy through a qualified healthcare provider.

Nasal Spray vs Injection — When Each Route Is Preferred

The choice between intranasal and injectable administration depends on which route the clinical data came from — for Semax and Selank, the original studied route was intranasal, meaning bioavailability and effect timelines in the literature reflect nasal administration; for PT-141, the FDA-approved route is subcutaneous (Vyleesi) after intranasal trials were halted in 2007 due to blood pressure concerns.

The "study the route that was actually studied" principle: if the clinical data for a compound comes from intranasal administration (Semax, Selank), the intranasal bioavailability and pharmacokinetics are what the research describes. Switching to subcutaneous injection changes the absorption profile — peak concentrations, timing, and tissue distribution all shift. For compounds where intranasal is the clinical standard, injection is a community-derived alternative without the same evidence base. For compounds where injection is the clinical standard (PT-141 as Vyleesi, kisspeptin in Imperial College research), intranasal is the community alternative.

For technical detail on injectable administration, see the injection technique guide and the SubQ vs IM comparison.

How to Administer a Peptide Nasal Spray — Technique and Dosing

Proper intranasal peptide administration requires 3 specific technique considerations — aim toward the outer nasal wall (not the septum), inhale gently (not sharply), and avoid nose-blowing for 15–30 minutes after — with typical doses ranging from 75–150 μg per spray for Semax and Selank, and up to 1.25 mg per spray for PT-141 formulations.

Typical Concentrations and Dosing

Selank's Russian clinical protocol used 250–300 μg intranasal doses in 14-day treatment courses — this is the dose range and cycle length with the strongest clinical evidence base. Semax dosing varies more widely in published literature, with cognitive and neuroprotective protocols commonly using 200–600 μg/day divided into 1–3 doses.

Administration Technique — Step by Step

1. Prime a new spray pump — 2–3 test sprays into the air to fill the delivery chamber. Skip this for a pump that's already primed.

2. Clear nasal passages gently — blow your nose before administration. Congestion significantly reduces absorption.

3. Tilt head slightly forward — not back. Backward tilt drains peptide down the throat where it is degraded by saliva and digestive enzymes.

4. Insert the spray nozzle tip into one nostril — aim toward the outer wall (lateral side), not toward the septum (the midline wall between nostrils). The septum has less vascularized mucosa and more sensitivity to irritation.

5. Spray once while inhaling gently through the nose. Do not sniff sharply — sharp inhalation drives the peptide past the mucosa into the throat, reducing absorption.

6. Wait approximately 30 seconds between sprays to allow initial absorption before administering a second spray.

7. Administer the second spray in the other nostril using the same technique.

8. Avoid blowing your nose for 15–30 minutes after administration. Nose-blowing removes peptide that hasn't yet absorbed.

Concentration Accuracy and Storage

Compounded nasal spray concentration varies widely between suppliers and compounding pharmacies. An "intranasal Selank 0.1%" vial may actually contain anywhere from 0.05% to 0.15% depending on the source. For users with access to independent testing, verify the concentration matches the label. See Peptigrity's independent lab test database for purity verification data across research peptide vendors.

For users making their own intranasal solutions from lyophilized peptide powder, the process parallels injection reconstitution — see the reconstitution guide. Storage follows the same principles as reconstituted injectables: refrigerated between uses, discarded if the solution becomes cloudy or develops sediment. See the peptide storage guide for full storage parameters.

Safety, Side Effects and Quality Considerations

The safety profile of intranasal peptides is generally favorable — most users experience only mild local effects (nasal irritation, congestion) — but two compound-specific considerations stand out: PT-141's intranasal route was halted by the FDA in 2007 due to blood pressure variability, and product quality across compounded nasal sprays varies widely enough that independent lab testing is essential.

Local Effects

Rhinitis, nasal congestion, local irritation, and dryness of the nasal passages are the most common intranasal peptide side effects. These are typically mild and transient — they improve as the mucosa adapts, usually within the first few days of a protocol. Switching which nostril receives the first spray of each session can reduce localized irritation.

Systemic Effects by Compound

Semax and Selank: Generally well-tolerated across both research and clinical use. Mild headache and occasional fatigue are the most commonly reported systemic effects. No significant cardiovascular, hepatic, or renal effects have been documented in published trials.

PT-141: The compound-specific safety concern that defines this category. Phase II intranasal trials documented variable blood pressure responses — transient hypertension in some subjects — that were unpredictable enough for the FDA to halt intranasal clinical development in 2007. Subcutaneous bremelanotide (Vyleesi) shows more consistent absorption kinetics and a more predictable BP profile, which is why it was the route that achieved FDA approval in 2019. Users with uncontrolled hypertension or cardiovascular disease should avoid intranasal PT-141 specifically.

Kisspeptin: Produces dose-dependent hormonal responses (LH/FSH surge) rather than conventional side effects — this is a pharmacological effect, not an adverse event per se, but the endocrine impact means kisspeptin should not be used casually.

Bioavailability Variability

Intranasal bioavailability is significantly affected by nasal condition. Active rhinitis, chronic congestion, deviated septum, or recent upper respiratory infection can reduce absorption by meaningful percentages. This creates inconsistency: the same dose administered on a congested day produces lower blood levels than on a clear day. For users with chronic nasal issues, the intranasal route may not be the optimal route — injectable alternatives exist for most of these compounds.

Enzyme Barrier

The olfactory epithelium contains proteolytic enzymes that degrade peptides before absorption. Leucine aminopeptidase, dipeptidyl peptidase, and carboxypeptidases in nasal mucus can cleave peptide chains, reducing bioavailability. This is why the <5% bioavailability holds for most peptides — the enzyme barrier is the rate-limiting step. Compounds with structural modifications that resist proteolysis (like Selank's Pro-Gly-Pro C-terminal extension) achieve dramatically higher bioavailability because they survive the enzyme barrier.

Product Quality

Compounded nasal spray concentration accuracy is a recurring issue in the research peptide market. A vial labeled as 0.1% Selank may contain significantly more or less than the labeled amount. For users who want to verify what they're actually administering, independent HPLC testing is the standard method. See how to verify peptide quality before you buy for the full process, and Peptigrity's lab test database to cross-reference vendor purity claims against independent testing data.

Regulatory Status

None of these compounds are FDA-approved for human use in the United States, with the exception of subcutaneous bremelanotide (Vyleesi). Intranasal compounded formulations exist in a regulatory gray area — they are legal for research purposes but are not FDA-evaluated for safety or efficacy at the compounded concentration. For users in jurisdictions where compounding pharmacies can legally supply these compounds (with a valid prescription), that pathway provides stronger quality control than research-chemical purchases.

Frequently Asked Questions

Why is Semax a nasal spray instead of an injection?

Semax was developed and clinically approved in Russia as a nasal formulation because its target is the central nervous system. The compound modulates BDNF (brain-derived neurotrophic factor), neurotransmitter systems, and neuroprotective pathways — all of which operate inside the brain. Intranasal administration provides direct access to the CNS via the olfactory and trigeminal nerve pathways, bypassing the blood-brain barrier. This produces meaningfully higher brain concentrations than peripheral injection would achieve, because injected peptides must cross the BBB (a significant restriction for many neuropeptides) to reach CNS targets. Injectable Semax exists in community protocols, but the clinical and pharmacokinetic literature is based on intranasal administration — using the same route as the published research preserves the expected effects.

What is the bioavailability of intranasal Selank?

Published rat pharmacokinetic studies (Zolotarev et al., 2005–2006) using radiolabeled Selank documented approximately 92.8% systemic bioavailability via the intranasal route, with detectable blood levels appearing within 30 seconds of administration. Maximum rat brain uptake reached approximately 1.04% of the administered dose. These numbers are exceptionally high for a peptide drug — most intranasal peptides show <5% bioavailability. Selank's unusual performance reflects three factors: its small molecular weight (751 Da), its hydrophilic properties that favor mucosal absorption, and the stabilizing effect of its Pro-Gly-Pro C-terminal extension, which resists proteolytic degradation in nasal mucus.

Can I inject Semax or Selank instead of using a nasal spray?

Technically yes — both compounds are used subcutaneously in community protocols. However, the published clinical data for both peptides (Russian clinical approval and the majority of pharmacokinetic research) is based on intranasal administration. Switching to subcutaneous changes the absorption profile: systemic bioavailability typically increases (as with any SubQ peptide), but the direct nose-to-brain CNS delivery pathway is bypassed. For compounds whose primary mechanism depends on CNS action — like Semax (BDNF modulation) and Selank (GABAergic effects) — this is a meaningful difference. Using SubQ with these compounds means operating outside the evidence base that supports their use. Users who prefer injection should consider whether the research that convinced them to try the peptide in the first place was done at the route they're planning to use.

Why did the FDA halt intranasal PT-141 trials?

During Phase II clinical trials in the mid-2000s, intranasal PT-141 (bremelanotide) demonstrated dose-dependent efficacy for erectile dysfunction at 7–15 mg doses. Efficacy was real — doses of 7.5 mg and above produced statistically significant improvements in IIEF scores. However, the intranasal formulation also produced variable blood pressure responses — particularly transient hypertension — that the FDA deemed too unpredictable for approval. The variability was the problem, not the mechanism itself. Development pivoted to subcutaneous administration, which showed more consistent absorption kinetics and a more predictable cardiovascular profile. Subcutaneous bremelanotide (Vyleesi) received FDA approval in 2019 for hypoactive sexual desire disorder in premenopausal women. Intranasal PT-141 compounded formulations still exist for research use, but they carry the same BP variability that stopped the original clinical program.

Does nasal congestion affect peptide absorption?

Yes — significantly. Active congestion, rhinitis, deviated septum, or upper respiratory infection all reduce nasal mucosa absorption efficiency. A congested user taking the same intranasal dose may absorb substantially less than an uncongested user because the peptide cannot reach the mucosal surface effectively. This creates dose-to-effect inconsistency: the same protocol produces different results depending on nasal condition. For users with chronic congestion or frequent upper respiratory issues, the intranasal route may not provide reliable results. Injectable alternatives exist for most of these compounds — subcutaneous Semax and Selank are community-used routes, and subcutaneous PT-141 (as Vyleesi) is the FDA-approved alternative. Users with temporary congestion can simply wait until nasal passages are clear before administration.

This article is for educational and informational purposes only and does not constitute medical advice. The peptides discussed are investigational compounds not approved by the FDA for human use, with the exception of subcutaneous bremelanotide (Vyleesi). Intranasal compounded formulations exist in a regulatory gray area and are not FDA-evaluated for safety or efficacy at the compounded concentration. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.